Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jul 15;24(9):1325-32.
doi: 10.1002/mds.22586.

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

Matthew Menza  1 , Roseanne DeFronzo Dobkin, Humberto Marin, Margery H Mark, Michael Gara, Steven Buyske, Karina Bienfait, Allison Dicke
Affiliations
Randomized Controlled Trial

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

Matthew Menza et al. Mov Disord. .

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease affecting up to one million individuals in the United States. Depression is found in 40 to 50% of these patients and is associated with a variety of poor outcomes for both patients and their families. Despite this, there are few evidence-based data to guide clinical care. This was an NIH-funded, randomized, controlled trial of paroxetine, nortriptyline, and placebo. It included an 8 week acute phase and a 16 week blind extension phase. This report details the impact of depression treatment on quality of life (QoL) and disability in the acute and extension phase of this study. Secondary outcomes included relapse, tolerability, safety, and the impact of depression treatment on PD physical functioning. Patients who had improvement in depression, compared with those who did not, had significant gains in measures of QoL and disability (PDQ-8, P = 0.0001; SF-36, P = 0.0001) at 8 weeks and maintained their gains in the extension phase. Patients who were on active drug were significantly less likely to relapse in the extension phase than those on placebo (P = 0.041). Though relatively modest in size, this trial provides the first controlled data on the impact of treatment of depression on QoL and disability in PD. It suggests that successfully treating depression in PD leads to important, sustained improvements in these outcomes and that patients who improve on antidepressants are less likely to relapse than are patients who initially improve on placebo.

PubMed Disclaimer

Figures

Chart 1
Chart 1
Patient flow diagram
See this image and copyright information in PMC

References

    1. Marras C, Tanner CM. Epidemiology of Parkinson's disease. In: Watts RL, Koller WC, editors. Movement disorders: Neurologic principles & practice. 2nd ed. New York: McGraw- Hill; 2004. pp. 177–195.
    1. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Dis. 2008 Jan 30;23(2):183–189. - PubMed
    1. Weintraub D. Depression in Parkinson’s disease. In: Menza M, Marsh L, editors. Psychiatric Issues in Parkinson's Disease: A Practical Guide. London: Taylor & Francis; 2006.
    1. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24;69(4):342–347. - PMC - PubMed
    1. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc. 1997;45(7):844–849. - PubMed

Publication types

MeSH terms